TipRanks on MSN

Lineage Cell Therapeutics receives iPSC line from Factor Bioscience

Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...
Business Wire

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Yahoo Finance

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

CARLSBAD, Calif., November 06, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell ...
Forbes

Data Lineage Could Be Your Most Strategic AI Investment

Forbes contributors publish independent expert analyses and insights. Gary Drenik is a writer covering AI, analytics and innovation. AI rarely fails because of bad models alone. More often it fails ...
Fierce Pharma

3 biopharma CEOs explain why they are 'authentically optimistic' for 2026

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...
Hosted on MSN

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans

CEO Brian Culley highlighted the progress of OpRegen, noting its differentiation from current anti-complement therapies for dry AMD. He emphasized, “OpRegen has shown evidence of both anatomical and ...